Guardant Health Collaborated with AnHeart Therapeutics to Develop Guardant360 CDx and Guardant360 TissueNext for Taletrectinib 


The companies collaborated for the development, regulatory approval & commercialization of Guardant360 CDx & Guardant360 TissueNext assays as CDx for taletrectinib in the US & EU
The focus of the collaboration is on the use of the Guardant tests for genomic profiling to identify patients who have the particular tumor mutations targeted by taletrectinib
Taletrectinib (ROS1 inhibitor) received the BTD from the US FDA on Aug 2022 for advanced or metastatic ROS1+ NSCLC. The results showed excellent potency against crizotinib resistance, good brain penetration & intracranial antitumor activity, and favorable safety profiles in ROS1 fusion-positive NSCLC patients with few neurological adverse events

Ref: Businesswire | Image: Guardant Health

Related News:- Guardant Health Receives the US FDA’s Approval of Guardant360 CDx Liquid Biopsy Test for Breast Cancer